The DOI matches its Crossref record.
Clinical development times for innovative drugs
Open accessAbstract
New drug development is a race against the clock as soon as the first patents are filed, and understanding the potential timings from first-in-human studies to regulatory approval is crucial for strategic planning. Here, we use information gathered from US FDA review documents to provide insight into the timeframes of successful drug development programmes in the past decade. We define clinical development time as the number of days between the initiation of first-in-human clinical studies and regulatory marketing authorization, and we focus on the development of innovative drugs — those products that are being marketed for the first time that contain a new molecular entity or new active moiety (see Supplementary Box 1 for details of the dataset and analysis, and Supplementary Table 1 for the dataset). We also investigate how FDA regulatory programmes may affect this process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The next generation of evidence-based medicine
Subbiah, V. (2023) · Nature Medicine · doi:10.1038/s41591-022-02160-z · Cited by 544
Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice
Khera, R., Oikonomou, E. K., Nadkarni, G. N., Morley, J. R., Wiens, J., Butte, A. J., & Topol, E. J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.003 · Cited by 264
Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
Floresta, G., Zagni, C., Gentile, D., Patamia, V., & Rescifina, A. (2022) · doi:10.20944/preprints202203.0032.v1 · Cited by 67
“Commonly, it takes up to 15 years from the design of a single drug to reach the market, and less than 15% of selected compounds that are tested on humans, are later proved as safe and effective and can be finally used [5,6].”
BackgroundBentwich, I. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103515 · Cited by 22
Metadata
- Authors
- Brown, D. G., Wobst, H. J., Kapoor, A., Kenna, L. A., & Southall, N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2021-11-10
- Volume
- 21
- Issue
- 11
- Pages
- 793-794
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W3213042299
- Cited by
- 173
- References
- 0
- FWCI
- 17.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical development times for innovative drugs. https://app.cochat.ai/papers/10.1038/d41573-021-00190-9
- The paper
- Brown, D. G., Wobst, H. J., Kapoor, A., Kenna, L. A., & Southall, N. (2022). Clinical development times for innovative drugs. Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-021-00190-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.